Blood Product Industry Records Steady Growth due to Rising Product Prices (2014-2017)

Share Article

Marketresearchreports.biz has announced the addition of a new research study on the global and China blood product industry titled China Blood Product Industry Report 2014-2017 to its offering.

The report analyzes the timeline of the global blood product industry, including the milestones, important trends, and opportunities to watch out for in the forecast period.

The China blood product industry is segmented into human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor VIII, hepatitis B immunoglobulin, human prothrombincomplex, tetanus immunoglobulin, and human rabies immunoglobulin. They key growth driver for the blood product industry are plasma resource reserves and control. Owing to stock consumption, poor utilization of new plasma stations, and stoppages in production, plasma volume in China blood products market dropped by 2.8% in 2013 as compared to last year. The volume of entire lot release also slumped by 7% year on year.

View Full Report at http://www.marketresearchreports.biz/analysis/211596

Stoppages in manufacturing contributed massively to this decrease. The companies on a manufacturing break were Guangdong Wellen Biological Pharmaceutical Co., Ltd. and GuizhouTaibang Biological Products Co., Ltd. –forupgradation and reconstruction – whileShanghai RAAS Blood Products Co., Ltd.,was terribly affected by floods.

However, human coagulation factor VIII achieved a high growth rate in lot release in 2013. In the same year, production of human coagulation factor VIII reached 526,000 bottles, up by 44.5% as compared to last year as two manufacturers of human coagulation factor VIII CNBG, Shanghai Institute of Biological Products and Shandong Taibang, were granted an approval.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/211596

Most China-based blood product companies recorded steady growth rates despite a minor drop in sales volume and output. It was only possible to maintain a reasonable growth due to an increase in prices of blood products. In the same period, blood coagulation factor VIII and fibrinogen segments grew by 50% year-on-year.

The report on China blood product industry profiles some of the key players such as China Biologic Products Inc., Shandong Taibang Biological Products Co., Ltd., Guizhou Taibang Biological Products Co., Ltd., Xi'an Huitian Blood Products Co., Ltd., Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., and Chengdu Rongsheng Pharmaceutical Co., Ltd. Thereport provides an insight into their operation, revenue structure, customers and suppliers, investments, and research and development of their various upcoming products.

Explore All Research in China Market Research Reports at http://www.marketresearchreports.biz/publisher/67

Ever since the Ministry of Health excluded blood products production facilities with less than 6 registered products and the blood products production units that are engaged in immunization projects at a national level with 5 registered blood varieties, the China blood product industry has got even more competitive in aspects of quality and cost. Owing to these changes, the China blood product industry is witnessing a surge of blood products of superior quality. China-based players are looking at acquiring small companies to gain a competitive advantage in the market.

Related Reports

China Recombinant Protein Drug Industry Report, 2014-2017

View Full Report at http://www.marketresearchreports.biz/analysis/232274

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/232274

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

China Pharmaceutical Excipients Industry Report, 2014-2017

View Full Report at http://www.marketresearchreports.biz/analysis/232334

China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

Among them, the traditional pharmaceutical excipients --gelatin capsules are involved with adequate supply and large export volume. In H1 2014, China’s gelatin capsule export volume amounted to 1,427.5 tons and the export value hit USD32.408 million. However, China still relies on the import of film-coated powder, polyvinylpyrrolidone (PVP) and other new-type high-end pharmaceutical excipients.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/232334

Currently, pharmaceutical excipients account for about 2%-3% of China's total output value of pharmaceutical preparations. Chinese pharmaceutical excipient market size reached about RMB26.35 billion in 2013 and is expected to be RMB54.83 billion in 2017.

About MarketResearchReports.biz:

Marketresearchreports.biz ( http://www.marketresearchreports.biz/ ) is the most comprehensive collection of market research reports, supporting clients’ market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.

Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, Marketresearchreports.biz has built a veritable reputation for fulfilling the most exacting market research needs.

Contact:

State Tower
90 State Street,
Suite 700, Albany
NY 12207, United States
Toll Free: 866-997-4948
Email: sales(at)marketresearchreports(dot)biz

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Michell Thoras

Sheela AK
Follow us on
Visit website